Aficamten · Myqorzo
Small molecule
Evidence outlook
Approved: Hypertrophic Cardiomyopathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in eligible adults
- Symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults
- Adults with NYHA class II-III obstructive hypertrophic cardiomyopathy, to improve exercise capacity and symptoms
Company guidance: regulatory filing expected Q4 2026 (Cytokinetics, 4 Nov 2026). “Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04783766 NCT04783766 · Hypertrophic Cardiomyopathy Run by former owner Corxel Pharmaceuticals Registry: NCT04783766 | 1 | Subject incidence of Adverse Event (AE), Serious Adverse Event (SAE) (SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23); Reduced Left Ventricular Ejection Fraction (LVEF) (SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23) 2021-08-05 | 35 mild treatment-emergent AEs in 14 participants (50%); no serious AEs and no LVEF fall below 50%. | not yet graded | link ↗ |
View 2 more trials
MAPLE-HCM NCT05767346 · Hypertrophic Cardiomyopathy This randomized, triple-blind, active-controlled Phase 3 trial (n=175) compared aficamten with the beta-blocker metoprolol succinate in adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint, change in peak oxygen uptake on exercise testing at 24 weeks, improved significantly more with aficamten than metoprolol (mean difference 2.30 mL/kg/min, p<0.0001). Registry: NCT05767346 | 3 | Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24) 2025-02-28 | Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) | Reliable signal | link ↗ |
SEQUOIA-HCM NCT05186818 · Hypertrophic Cardiomyopathy This was a randomized, double-blind, placebo-controlled Phase 3 trial in 282 adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint, change in peak oxygen uptake on exercise testing at 24 weeks, improved significantly more with aficamten than placebo (mean difference 1.74 mL/kg/min, p<0.0001). Registry: NCT05186818 | 3 | Change From Baseline in pVO2 at Week 24 (Baseline to Week 24) 2023-11-10 | Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Cardiac myosin (inhibitor) drugs
Mavacamten, HRS-1893, Delocamten, Ulacamten. Compare all 5 Cardiac myosin (inhibitor) drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Hypertrophic Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Aficamten (Myqorzo): this drug | Approved | Small molecule | Cardiac myosin (inhibitor) | Reliable signal | NCT05767346: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) NCT05186818: Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25) | |
| Mavacamten (Camzyos) | Approved | Small molecule | Cardiac myosin (inhibitor) | Partial signal | NCT04349072: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-1893 | Phase 3 | Undisclosed | Cardiac myosin (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Delocamten | Phase 2(overall) | Small molecule | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ninerafaxstat (IMB-101) | Phase 2 | Small molecule | Cardiac fatty-acid oxidation | not yet graded | No reviewed efficacy summary in this indication | |
| Ulacamten | Phase 2(overall) | Small molecule | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Myqorzo (Aficamten) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
2030 (1)
January 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent